Previous Article | Next Article 
Journal of Virology, July 2001, p. 5851-5859, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5851-5859.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Nef Enhances Human Immunodeficiency Virus Type 1 Infectivity
Resulting from Intervirion Fusion: Evidence Supporting a Role for
Nef at the Virion Envelope
Jing
Zhou and
Christopher
Aiken*
Department of Microbiology and Immunology,
Vanderbilt University School of Medicine, Nashville, Tennessee
37232-2363
Received 13 December 2000/Accepted 30 March 2001
 |
ABSTRACT |
The human immunodeficiency virus type 1 (HIV-1) accessory protein
Nef stimulates viral infectivity by facilitating an early event in the
HIV-1 life cycle. Although no structural or biochemical defects in
Nef-defective HIV-1 particles have been demonstrated, the Nef protein
is incorporated into HIV-1 particles. To localize the function of Nef
within the virus particle, we developed a novel technology involving
fusion of enveloped donor HIV-1 particles bearing core defects with
envelope-defective target virions bearing HIV-1 receptors. Although
neither virus alone was capable of infecting CD4+ target
cells, the incubation of donor and target virions prior to addition to
target cells resulted in infection. This effect, termed "virion
transcomplementation," required a functional Env protein on the donor
virus and CD4 and an appropriate coreceptor on target virions. To
provide evidence for intervirion fusion as the mechanism of
complementation, experiments were performed using dual-enveloped HIV-1
particles bearing both HIV-1 and ecotropic murine leukemia virus
(E-MLV) Env proteins as donor virions. Infection of CD4-negative target
cells bearing E-MLV receptors was prevented by HIV-1 entry inhibitors
when added before, but not after, incubation of donor and target
virions prior to the addition to cells. When we used Nef+
and Nef
donor and target virions, Nef enhanced infection
when present in donor virions. In contrast, no effect of Nef was
detected when present in the target virus. These results reveal a
potential mechanism for enhancing HIV-1 diversity in vivo through the
rescue of defective viral genomes and provide a novel genetic system for the functional analysis of virion-associated proteins in HIV-1 infection.
 |
INTRODUCTION |
Nef is a highly conserved accessory
protein encoded by human immunodeficiency virus type 1 (HIV-1), HIV-2,
and simian immunodeficiency virus (SIV) and plays a crucial role in
primate lentiviral virulence. Nef-defective SIV is strongly attenuated
in adult rhesus macaques (16). Furthermore, some long-term
nonprogressors of HIV-1 infection harbor viruses bearing defective
nef genes, suggesting that Nef is required for HIV-1
pathogenesis (17, 23, 29, 30). Finally, in a transgenic
mouse model of HIV-1 disease, Nef was the sole determinant of
pathogenesis (14).
In cell culture, Nef accelerates HIV-1 replication, downregulates cell
surface CD4 and class I major histocompatibility complex expression,
and influences T-cell activation (for reviews, see references
12 and 28). Although the relative importance
of each of these activities in AIDS pathogenesis has not been
established, the ability of Nef to enhance HIV-1 replication is of
obvious interest, but the mechanism by which this occurs is unclear.
Nef-defective particles are approximately 10-fold less infectious than
wild-type HIV-1 when tested in single-cycle infection assays (10,
24). The reduction in infectivity has been localized to an early
postentry defect of Nef mutant virions in target cells (2, 9,
32). Although no structural or biochemical defects in
Nef
HIV-1 particles have been detected, the Nef protein
itself is present within virions and is cleaved by the viral protease
(4, 27, 36). However, cleavage of Nef is not required for
the enhancement of infectivity (8). A significant fraction
of virion-associated Nef localizes to the HIV-1 core, suggesting that
Nef may facilitate postentry events by modifying the core
(18). Nef also can be packaged into heterologous
retroviruses such as MLV, suggesting that Nef is passively incorporated
into HIV-1 particles at the time of budding due to its localization to
the plasma membrane of infected cells (8). Consistent with
this hypothesis, the amino-terminal membrane binding domain of Nef,
containing a myristylation signal and a stretch of basic residues, is
sufficient to mediate virion incorporation of a heterologous reporter
protein (35). Although Nef localizes to the HIV-1 core, it
is not known whether virion incorporation of Nef is required for
infectivity enhancement.
Infection by enveloped viruses requires interactions between a fusion
protein on the virion surface and receptors on the plasma membrane of
the target cell. Engagement of the receptor induces conformational
changes in the viral Env proteins, resulting in exposure of a fusion
peptide and the mixing of viral and cellular lipids, thereby catalyzing
membrane fusion events required for viral entry. Recently, it was
reported that retroviral Env proteins can be replaced by their cognate
receptors, resulting in particles that specifically infect cells
expressing the viral Env proteins (3, 13). Infection by
these particles, termed "receptor pseudotypes," demonstrates that
the orientation of the fusion protein-receptor interaction can be
functionally reversed, suggesting that a specific directionality of the
fusion reaction is not an absolute requirement for productive virus
entry. Based on these reports, we hypothesized that
receptor-pseudotyped virions should also be capable of fusing with
enveloped virions and that the fusion products would be infectious on
target cells bearing appropriate viral receptors. This system, termed
"virion transcomplementation," would allow investigation of the
mechanism of action of virion-associated proteins such as Nef. In this
study, we detected intervirion fusion events by assaying infection
resulting from incubation of enveloped particles ("donor virions")
containing defective cores with receptor-pseudotyped target virions.
Infection was enhanced by Nef only when produced with the donor
virions. These results demonstrate that infectivity enhancement by Nef
does not require its presence during viral core formation.
 |
MATERIALS AND METHODS |
Cells and viruses.
293T cells were used for production of
HIV-1 particles and were cultured at 37°C and 5% CO2 in
Dulbecco modified Eagle medium supplemented with fetal bovine serum
(10%), penicillin (50 IU/ml), and streptomycin (50 µg/ml) (D10
medium). Work with infectious HIV-1 was performed in a biosafety level
3 laboratory under P3 containment conditions. Viruses were produced
from 293T cells cultured in 100-mm dishes using a high-efficiency
calcium phosphate transfection procedure and cloned proviral DNA
(7). For production of receptor pseudotyped HIV-1
particles, Env-defective HIV-1 proviral DNA (10 µg) was cotransfected
with the tail-less CD4 expression vector CMX-44X (2 µg)
(22) and either pC-Fusin or pC-CCR5 (8 µg)
(11). For production of dual-enveloped donor HIV-1
particles carrying both HIV-1 Env and either vesicular stomatitis virus (VSV) or Ecotropic MLV (E-MLV) Env proteins, core-defective,
Env-competent HIV-1 proviral clones (10 µg) were cotransfected with
either pHCMV-G (40) or pSV-E-MLV-Env (19),
respectively (10 µg each plasmid). Viruses were collected from the
culture supernatants 2 days after transfection and were frozen in
aliquots at
80°C after passage through 0.45-µm (pore-size)
filters to remove cellular debris. P4 and Z24 cells (5)
are HeLa-derived HIV-1 indicator target cells expressing or lacking
human CD4, respectively, and were cultured at 37°C and 5%
CO2 in D10 medium. To produce Z24 cells expressing the
E-MLV receptor Rec-1 (Z24-Rec-1), the Rec-1 cDNA was first cloned into
the MLV retroviral vector pBABE-puro, and the vector was packaged into
pantropic MLV particles by cotransfection of 293T cells with the MLV
gag-pol expression vector
pSV
MLV-env
(19)
and pHCMV-G. Two days after transfection, viral supernatant was
harvested and used to infect Z24 cells in the presence of Polybrene (8 µg/ml) (Sigma). Transduced cells were selected in puromycin (2 µg/ml) (Sigma), and the resistant population of cells was used as
targets in quantitative infection assays of HIV-1 particles pseudotyped
by the E-MLV envelope proteins. P4 cells expressing CCR5 were produced
by a similar procedure using the pBABE.CCR5 retroviral vector
(11).
Viral clones.
The Env-defective proviral clone, designated
R9
E, was created by end filling the NdeI site in the
wild-type infectious HIV-1 clone R9, resulting in a frameshift at
residue 61 of Env. Virions produced from this clone are noninfectious
but can be pseudotyped by cotransfection with plasmids encoding HIV-1,
MLV, or VSV Env proteins. R9
E
N, lacking functional Env and Nef
genes, was created by transferring the SalI-BamHI
fragment from R9
E into the Nef-defective proviral clone R9
N. CA5
and CA6, encoding HIV-1 particles containing nonfunctional cleavage
sites between CA and NC, were provided by H.-G. Krausslich and have
been described elsewhere (39). CA5-BaL was created by
substituting the SalI-BamHI fragment, from the
CCR5-tropic HIV-1 isolate BaL, for the corresponding region in CA5,
thereby conferring CCR5 tropism to CA5. The unpublished HIV-1 proviral
clone R9.R18AN21A, encoding two point mutations in CA, was provided by
W. Sundquist. This construct produces HIV-1 particles that are
noninfectious due to formation of aberrant HIV-1 cores (U. von
Schwedler and W. Sundquist, personal communication). Nef-defective
versions of R9
E, CA5, and R9.R18AN21A (R9
E
N, CA5
N,
and R18AN21A
N, respectively) were created by closing the Nef
open reading frame by end filling of the unique XhoI site, resulting in a frameshift at codon 33 and expression of a truncated, nonfunctional Nef protein.
Infection assays.
The P4 cell line, a HeLa cell clone
engineered to express CD4 and an integrated LTR-lacZ
reporter construct (5), was used to detect HIV-1 infection
as previously described, with the following modifications. HIV-1 stocks
were diluted serially in D10 medium, and samples (0.125 ml) were added
to P4 target cells plated 1 day prior (20,000 cells per well in 48-well
plates). After 2 h, cultures were fed with an additional 0.5 ml of
D10 medium and cultured for an additional 48 h prior to X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) staining to detect infected cells. Infected cells were quantified by
counting stained cells using NIH Image software analysis of images
captured with a charge-coupled device camera equipped with a macro lens.
For virion transcomplementation assays, equal quantities (equivalent to
100 ng of p24) of donor and target virions were mixed and incubated at
37°C for 1 h prior to titration on indicator target cells. In
experiments where inhibitors were added after the mixing of viruses,
donor and target virions were first mixed and incubated at 37°C for
1 h, followed by the addition of the soluble CD4 or 2G12
anti-gp120 monoclonal antibody and incubation for an additional 30 min.
Infectivity was subsequently determined by titration on P4 or Z24-Rec-1
indicator target cells.
For analysis of HIV-1 infection by flow cytometry, an
env-defective HIV-1 proviral clone containing the gene
encoding green
fluorescent protein (GFP) (
15) was used for
producing receptor
pseudotyped target virions. Two days after infection
of Z24 target
cells, the cells were washed with phosphate-buffered
saline (PBS),
detached by trypsinization, and fixed in PBS containing
4% paraformaldehyde.
Cells were analyzed for GFP expression by flow
cytometry using
a Becton-Dickinson FACScalibur instrument after dead
cells and
debris were gated out using scatter
parameters.
Virus capture assays.
To detect HIV-1 incorporation of CD4,
CXCR4, and CCR5, Immunlon II 96-well enzyme-linked immunosorbent assay
(ELISA) plates (Dynex) were coated with anti-CD4, anti-CXCR4,
anti-CCR5, or anti-gp120-specific antibodies (5 µg/ml; 0.1 ml per
well) overnight at 37°C. After three washes with PBS, the wells were
subsequently blocked by incubation with PBS containing 1% bovine serum
albumin for 1 h at 37°C. The wells were then washed twice with
PBS, and receptor-pseudotyped or control HIV-1 particles were added (50 ng of p24 in 0.1 ml) and incubated at 37°C for 2 h. Unbound
virions were removed by three washes with PBS, and captured HIV-1
particles were removed by the addition of p24 ELISA sample diluent (PBS
containing 5% donor calf serum and 1% Triton X-100), and viral CA
antigen was quantified by p24 ELISA as previously described
(34).
 |
RESULTS |
Experimental strategy for detecting intervirion fusion.
Based
on a previous report that HIV-1 particles bearing CD4 and a coreceptor
can infect cells expressing the cognate HIV-1 Env proteins
(13), we reasoned that these receptor-pseudotyped virions might also be capable of fusing with enveloped HIV-1
particles. To test this idea, we designed a sensitive
complementation assay to detect intervirion fusion products (Fig.
1). In this system, HIV-1 particles
bearing defective cores were produced from proviral clones (CA5 and
CA6) containing multiple mutations in the Pr55Gag cleavage
sites between CA and NC, thereby blocking recognition by the viral
protease and preventing core maturation. The resultant virions carry
HIV-1 Env proteins on their surface and may function as
fusion-competent donor virions. The receptor-pseudotyped HIV-1 particles ("target virions") used in this system lacked HIV-1 Env
proteins but contain CD4 and the HIV-1 coreceptor, CXCR4. These
particles were produced by cotransfection of 293T cells with an
Env-defective HIV-1 proviral clone and plasmids encoding CD4 and CXCR4.
To ensure high-level CD4 expression in producer cells, a truncated form
of CD4 lacking the cytoplasmic domain was used to avoid downregulation
by Nef in the producer cells. Virus capture assays using antisera
specific for CD4, CXCR4, and CCR5 demonstrated that these proteins were
present on the virion surface only if the virus was produced from cells
overexpressing these proteins (Fig. 2).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Strategy for detecting fusion between core-defective
HIV-1 particles and receptor-pseudotyped HIV-1 particles. Defective
HIV-1 particles, lacking functional cores due to mutations in Gag
cleavage sites, are incubated with Env-defective HIV-1 particles
pseudotyped by CD4 and CXCR4. While neither virus is infectious itself,
fusion of the two virions is predicted to result in hybrid particles
bearing a functional core and HIV-1 Env proteins. The fused virions
should be capable of infecting CD4+ target cells bearing an
appropriate coreceptor.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Virus capture assay for CXCR4 and CCR5 on the surface of
HIV-1 particles. ELISA plates were coated with the indicated antibodies
(A, -CXCR4; B, -CCR5; C, -gp120; and D, -CD4), blocked with
bovine serum albumin, and virus samples were added and allowed to bind.
After a washing to remove unbound virions, captured HIV-1 was removed
by addition of 0.1 ml of lysis buffer and was quantified by p24 ELISA.
R9, wild-type HIV-1 particles; E(CD4), Env-defective particles
bearing CD4; E(CD4+CXCR4), Env-defective HIV-1 particles bearing CD4
and CXCR4; E(CD4+CCR5), Env-defective HIV-1 particles bearing CD4
and CCR5. The results shown are representative of two independent
experiments.
|
|
In agreement with a previous report (
13), control
experiments demonstrated that these receptor-pseudotyped HIV-1
particles
were competent for infection of cells expressing HIV-1 Env
proteins
in a coreceptor-dependent manner (data not shown). Whereas
neither
donor nor target virus alone was capable of infecting
CD4
+ target cells, fusion of the virions was predicted to
yield hybrid
particles containing a functional core (from the target
virion)
and Env proteins (from the donor virion) at their surface.
These
particles should therefore be capable of infecting
CD4
+ target cells and be scored in single-cycle infection
assays that
detect Tat expression in target
cells.
Infection of CD4+ target cells upon mixing of
core-defective HIV-1 particles with receptor-pseudotyped HIV-1
particles.
Assays of CA5 and CA6 particles alone demonstrated that
these viruses were poorly infectious on CD4+ target cells,
as were receptor-pseudotyped target virions. However, upon mixing of
donor and target virions, a dramatic enhancement of infection (16- to
100-fold) was observed (Table 1).
Infection by mixing of core-defective and receptor-pseudotyped
particles, termed "virion transcomplementation," required the
presence of CD4 and a coreceptor on target virions, as demonstrated by
the inability of Env-defective particles produced in the absence of these proteins (HIV-1
E) to serve as functional target virions (Fig.
3A). Using CXCR4-tropic donor virions,
significant infection was observed only when target virions contained
CXCR4, but not with target virions bearing CCR5. Similarly, mixing of
core-defective, CCR5-tropic HIV-1 particles (CA5-BaL) with target
virions resulted in infection that was enhanced by the presence of CCR5
on target virions (Fig. 3A). We conclude that mixing of enveloped HIV-1 particles with receptor-pseudotyped virions permits infection of
CD4+ target cells in a manner that requires an appropriate
Env-coreceptor interaction on donor and target virions, respectively.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Complementation of envelope-defective,
receptor-pseudotyped HIV-1 particles upon mixing with core-defective
virions
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Virion transcomplementation requires a matched HIV-1
envelope-coreceptor pair on donor and target virions. (A) Infection
assays were performed by mixing donor particles bearing CXCR4-tropic
(CA5) and CCR5-tropic (CA5-BaL) Env proteins with receptor-pseudotyped
target virions, and infection was tested using target cells bearing
both coreceptors. To demonstrate the requirement for CD4 and CXCR4 on
target virions, Env-defective HIV-1 particles lacking receptors
(HIV-1 E) were used as target virions. Appreciable levels of
infection were observed only when the target virions contained CD4 and
an appropriate coreceptor. (B) Requirement of the HIV-1 Env proteins on
donor virions and CD4 on target virions for infection of CD4-negative
target cells by intervirion fusion using dual-enveloped donor
particles. Core-defective particles bearing both HIV-1 and VSV Env
proteins virions [CA5(VSV) or CA6(VSV)] were mixed with
receptor-pseudotyped target virions, and the virus mixtures were used
to infect HeLa target cells lacking CD4 (Z24 cells). The mean values of
triplicate infections are shown; error bars represent one standard
deviation. Results are representative of at least two independent
experiments.
|
|
Virion transcomplementation occurs through intervirion fusion.
In light of these findings, we hypothesized that virion
transcomplementation occurs through the fusion of donor and target virions prior to fusion with target cells. An alternative hypothesis is
that infection occurs through a two-step mechanism in which enveloped
donor virions fuse with target cells, depositing HIV-1 Env proteins on
the cell surface and allowing subsequent fusion of receptor pseudotyped
target virions. To distinguish between these mechanisms, we created
core-defective donor virions carrying both HIV-1 and VSV Env proteins
by transfection of either CA5 or CA6 clones with a VSV-G-protein
(VSV-G) expression construct. The resulting particles, though
noninfectious themselves, resulted in infection of CD4-negative HeLa
cells (Z24 cells) upon mixing with receptor pseudotyped virions (Fig.
3B). Infection of CD4-negative cells indicated that entry was mediated
through the receptor for VSV-G. However, the presence of CD4 and
coreceptor on target virions was required for infection, as
demonstrated by inability of Env-defective HIV-1 particles lacking
these receptors to serve as targets (Fig. 3B). Fusion of HIV-1(VSV)
pseudotyped particles requires exposure to the low-pH environment of
endosomes, implying internalization through endocytosis for infection
by these particles (1). Therefore, it is unlikely that
infection was due to prior fusion of the enveloped particles with
target cells at the plasma membrane and subsequent fusion of
CD4-pseudotyped HIV-1 particles. Furthermore, the lack of infection
observed in the absence of CD4 and coreceptor on target virions
indicated that virion transcomplementation was not mediated by the
VSV-G protein. These results support intervirion fusion as the most
probable mechanism of infection.
To further probe the mechanism of virion transcomplementation, we
hypothesized that fusion of dual enveloped donor virions
with
receptor-pseudotyped target virions would result in infectious
particles that no longer require the activity of the HIV-1 Env
proteins
(Fig.
4). To test this hypothesis, we
created donor particles
bearing both HIV-1 and E-MLV envelope proteins,
and mixed these
particles with CD4-pseudotyped HIV-1 virions. The E-MLV
envelope,
rather than VSV-G, was specifically chosen for this purpose
to
avoid the possibility of incorporation of its cognate receptor,
which is not expressed in human cells, into target virions. The
mixed
virions infected target cells expressing the E-MLV receptor
Rec-1 but
lacking CD4, while neither donor nor target virus alone
was infectious
(data not shown).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 4.
Evidence for intervirion fusion as the mechanism of
complementation. (A) Strategy for infection of CD4-negative, Rec-1
expressing target cells by virion transcomplementation using donor
virions bearing both HIV-1 and E-MLV Env proteins. Virion
transcomplementation is predicted to result in particles that no
longer require the function of the HIV-1 Env proteins for infection of
target cells expressing the E-MLV receptor Rec-1. Infection should
therefore acquire resistance to specific inhibitors of HIV-1 entry. (B
and C) Resistance of intervirion fusion products to neutralization by
soluble CD4 ( ) and anti-gp120 monoclonal antibody 2G12 ( ).
Inhibitors were added at the indicated concentrations after premixing
of the two viruses. Infectivity was measured using CD4
target cells expressing Rec-1, the E-MLV receptor, and is represented
in units of infected cells per nanogram of p24 in the sample. (B)
Infection by mixing of donor and target virions. (C) Infection by
wild-type HIV-1.
|
|
To determine whether infection was resistant to HIV-1 entry inhibitors,
donor and target were mixed and preincubated at 37°C
to permit
intervirion fusion. Subsequently, either soluble CD4
or the
gp120-specific HIV-1 neutralizing antibody 2G12 was titrated
into
parallel samples. After further incubation to allow inhibitor
binding,
the samples were assayed on Rec-1-expressing target cells
to allow
infection using the E-MLV envelope protein. Neither inhibitor
exhibited
a significant reduction of infection by the mixed virions
(Fig.
4B). In
contrast, infection of CD4-expressing cells by wild-type
HIV-1
particles was efficiently blocked by low concentrations
of either
inhibitor (Fig.
4C). Preincubation of the E-MLV-pseudotyped
donor virus
with sCD4 prior to mixing with target virions resulted
in 98%
inhibition of infection, demonstrating the effectiveness
of the
inhibitor and further establishing the requirement for
a functional
HIV-1 Env protein for complementation (data not shown).
These results
demonstrate that infection in this system acquires
resistance to
inhibitors of HIV-1 entry, providing evidence for
intervirion fusion
prior to infection of target
cells.
Nef enhances infection resulting from virion
transcomplementation.
Nef enhances the infectivity of cell-free
HIV-1 particles when tested in single cycle assays, but the mechanism
by which Nef mediates this function is poorly understood. Infectivity
enhancement by Nef requires its expression in producer cells at the
time of HIV-1 particle formation, and although the Nef protein is
incorporated into HIV-1 particles, a functional role for
virion-associated Nef has not been demonstrated (2, 25,
27). To explore the potential role of virion-associated Nef in
HIV-1 infection, we employed the virion transcomplementation system
using Nef+ and Nef
donor virions (Fig.
5A). In this approach, core-defective
HIV-1 donor particles, containing or lacking Nef, are mixed with
CD4-pseudotyped, Nef-defective HIV-1 target virions. If Nef functions
within the virion, then transfer of Nef from donor particles to target
virions via intervirion fusion might result in enhanced infection,
assuming that Nef localized to its functional target within the hybrid particle.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of Nef on infection by virion
transcomplementation. (A) Strategy for detecting an effect of Nef in
the donor virus. Core-defective HIV-1 particles carrying Nef are
incubated with Nef-defective, receptor-pseudotyped target virions prior
to the addition to target cells. If Nef is functional within the HIV-1
particle, then transfer of Nef by intervirion fusion is predicted to
enhance infection. (B) Results of intervirion fusion assays for a
functional role of virion-associated Nef. Two core-defective HIV-1
clones (CA5, and the CA double point mutant R18AN21A) were rendered Nef
defective ( N) and used to produce donor virions. These particles
were incubated with Env-defective, Nef-defective virions pseudotyped
with CD4 and CXCR4 [ E N(4.X4)], and the mixtures were assayed
for infectivity on HeLa-CD4 target cells. The mean infectivity values
of triplicate determinations are shown as the number of infectious
units per nanogram of p24, with error bars representing one standard
deviation. The results demonstrated an approximately threefold
enhancement by Nef in the donor virions and are representative of three
independent experiments.
|
|
To test this idea, we employed two core-defective donor viruses. The CA
double point mutant R18AN21A forms aberrant cores,
probably due to
altered CA-CA interactions (U. von Schwedler and
W. Sundquist, personal
communication). HIV-1 proviral clones encoding
these mutations, as well
as the Pr55
Gag cleavage site mutant CA5, were rendered Nef
defective by closing
the Nef open reading frame at codon 36. Donor
virions were produced
from mutant proviruses encoding functional or
defective
nef genes,
and equal quantities of
Nef
+ or Nef

donor particles, as determined by
p24 ELISA, were added to Nef-defective
target virions
[

E

N(4.X4)]. After incubation at 37°C for 1 h,
the
mixtures were titrated on HeLa-CD4 target cells to quantify
infectivity. For both core-defective mutants, infection upon mixing
with receptor-pseudotyped, Nef-defective target virions was enhanced
by
approximately threefold when Nef was present within donor virus
particles (Fig.
5B). To examine the dose dependence of this effect,
we
repeated these experiments and varied the ratio of donor to
target
virions. At a 4:1 ratio, the effect of Nef increased to
approximately
fivefold (Table
2). Collectively, these
results
demonstrate that Nef can enhance HIV-1 infectivity even when
absent
during the time of viral core formation.
Infectivity of virion transcomplementation by Nef depends on the
pathway of entry into the target cell.
Based on previous results
from HIV-1 entry and pseudotyping experiments, it has generally been
assumed that Nef affects a step in the HIV-1 life cycle following
virus-cell fusion (2, 25, 32). However,
pseudotyping HIV-1 particles by VSV-G relieves the requirement
for Nef (1, 20), probably due to a difference in the
pathway of entry of HIV-1(VSV) pseudotyped particles (6). To determine whether Nef present in the donor virus might enhance the
efficiency of intervirion fusion, we tested whether donor virions
containing both HIV-1 and VSV envelope proteins exhibited a
dependence on Nef in the virion transcomplementation assay system. Nef+ and Nef
donor particles bearing HIV-1
and VSV Env proteins were incubated with Nef-defective target virions
at 37°C in medium buffered to pH 7.4 with HEPES, thereby preventing
VSV-G-induced intervirion fusion. The virus mixtures were then assayed
for infection of CD4-negative target cells. In contrast to donor
virions containing only the HIV-1 envelope, intervirion fusion products
were not significantly enhanced by Nef when infection required entry
catalyzed by VSV-G (Fig. 6). Experiments
employing a target virus encoding GFP and flow cytometric analysis for
detection of GFP expression in target cells confirmed this result and
demonstrated that the integrated provirus is derived from the target
virus genome (Table 3).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 6.
Virion transcomplementation is minimally dependent on
Nef when donor virions are pseudotyped by VSV-G. Core-defective virions
containing or lacking Nef were produced by contransfection with or
without a VSV-G expression vector, resulting in particles bearing VSV
and/or HIV-1 Env proteins. These particles were incubated with
receptor-pseudotyped target virions prior to addition to CD4-negative
target cells, allowing infection only through the VSV-G receptor. The
mean infectivity values of triplicate determinations are shown as the
number of infectious units per nanogram of p24, with error bars
representing one standard deviation. In contrast to the results with
nonpseudotyped donor virions (Fig. 5), only a relatively small
enhancement by Nef was observed in this system.
|
|
We have previously shown that pseudotyping by VSV-G results in
dramatically enhanced infectivity of HIV-1 particles (
1).
The virion transcomplementation assays using VSG-G pseudotyped
donor
virions also resulted in much higher levels of infection.
Therefore, to
test whether the minimal contribution of Nef to
infection by the VSV-G
pseudotyped donor virions resulted from
the relatively higher
infectivity of these virions, we repeated
the experiment using donor
virions containing reduced quantities
of VSV-G. Reduction of VSV-G on
donor virions resulted in decreased
infectivity upon mixing with target
virions without increasing
the effect of Nef in this system (Fig.
7). As an additional control,
pseudotyped
donor virions bearing both HIV-1 and A-MLV Env proteins
were tested.
Like the nonpseudotyped donor virions, the infectivity
resulting from
the use of the CA5(A-MLV) donor virions was enhanced
by approximately
threefold by Nef. These results argue against
a role of Nef on the
efficiency of intervirion fusion itself,
and demonstrate that the
requirement for Nef in infection by virion
transcomplementation
exhibits the same envelope dependence as
enhancement of normal HIV-1
infection by Nef.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 7.
The minimal effect of Nef on virion transcomplementation
using VSV-G-pseudotyped donor virions is not a consequence of overall
enhancement by VSV-G. Nef+ and Nef donor
virions (CA5 and CA5 N, respectively) were produced by cotransfection
with the indicated quantities of VSV-G expression plasmid and mixed
with receptor-pseudotyped target virions. Infection was assayed as in
Fig. 6. As controls, nonpseudotyped donor virions (HIV-1) and A-MLV
pseudotyped virions were used as donor virions, and infection was
scored on CD4+ and CD4 cells, respectively.
The duplicate bars represent independent preparations of donor viruses
assayed in parallel.
|
|
The ability of Nef to enhance infection through virion
transcomplementation is specific to donor virus particles.
To
determine whether the effect of Nef was specific to donor or target
virus particles, virion transcomplementation assays were performed
using Nef+ and Nef
target virus particles.
Two donor virus pairs, containing either the CA5 or R18AN21A mutations,
respectively, were used in these experiments. Mixing of donor and
target virions resulted in levels of infection that were enhanced by
approximately threefold when the donor virus expressed Nef (Fig.
8). Surprisingly, the efficiency of
infection was not significantly affected by the Nef status of the
target virus. Control experiments demonstrated that HIV-1 particles
produced from the Env-defective proviral clones were strongly dependent
on Nef when pseudotyped with either HIV-1 or amphotropic MLV envelope
glycoproteins, confirming the Nef status of the proviral clones used in
these experiments (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 8.
Nef enhances infection through a specific effect on the
donor virus. Equal quantities of Nef+ and Nef
donor viruses were mixed with Nef+ and Nef
target viruses [ E(4.X4) and E N(4.X4), respectively], and
infection was scored on CD4+ target cells. The mean values
of triplicate infections are shown, with error bars representing one
standard deviation. The results are representative of three independent
experiments.
|
|
 |
DISCUSSION |
In this report, we describe a novel genetic assay to detect fusion
events involving Env-defective HIV-1 particles bearing the HIV-1
receptor complex and core-defective HIV-1 particles bearing functional
Env proteins. Neither virus was independently capable of infecting
CD4+ target cells. However, mixing of the virions
dramatically enhanced infection to levels that represent approximately
5% of the wild-type HIV-1 infectivity. Although the overall efficiency
of virion transcomplementation was relatively low, intervirion fusion
events were readily detected using a sensitive single-cycle assay of
infection. Infection required CD4 and an appropriate coreceptor on
target virions and a functional Env protein complex on donor virions.
In a related study, Sparacio et al. also reported infection upon mixing
of receptor-pseudotyped particles and enveloped particles
(33). However, in the latter study, alternative mechanisms
of complementation not involving intervirion fusion were not excluded.
Here we demonstrate that virion transcomplementation results in
acquisition of resistance to inhibitors of HIV-1 entry when the donor
virions carry an additional heterologous Env protein. These results
provide strong evidence for intervirion fusion as the mechanism of
infection in this system.
The finding that intervirion fusion occurs in vitro has important
implications for understanding the mechanism of HIV-1 entry. For some
enveloped viruses, fusion systems have been reconstituted using
artificial liposomes or planar lipid bilayers and virus particles,
allowing precise control of the composition of the target membranes
(21, 37, 38). For these viruses, fusion has been
demonstrated in the absence of a target cell, indicating that
cytoskeletal components or molecules other than the known viral
receptor are not required for fusion. For HIV-1, it has been shown that
receptor-pseudotyped particles can fuse with target cells expressing
the viral Env proteins, demonstrating the lack of a strict orientation
dependence of the virus-cell fusion machinery (13). Our
finding that virions are capable of fusing with each other in the
absence of a target cell extends these observations by demonstrating
that specific cellular structures, such as an intact cytoskeleton, are
not absolute requirements for HIV-1-catalyzed membrane fusion.
Virion transcomplementation also represents a potential mechanism for
enhancing HIV-1 diversity in vivo. HIV-1 persistence is likely promoted
by the rapid evolution of viral variants. Viral evolution represents a
major obstacle for vaccine design and for drug therapy due to the ease
in which viral escape mutants are generated. The observation that
intervirion fusion results in temporary rescue of
env-defective genomes suggests that this mechanism might
increase the probability of reversion through the acquisition of
additional mutations, thereby facilitating viral evolution in vivo. In
our experiments, target virions were produced in cells overexpressing
both CD4 and HIV-1 coreceptors. Whether virion transcomplementation can
be detected using target virions produced in primary cells remains to
be determined.
In this study, we employed the intervirion fusion system to probe the
mechanism by which Nef enhances the infectivity of HIV-1 particles.
Infection was enhanced when Nef was present at the time of donor virus
production. Studies in our laboratory and others have concluded that
nef-defective particles are competent for entry into target
cells but are inhibited at a postentry step prior to, or concomitant
with, initiation of reverse transcription, such as viral uncoating
(2, 9, 32). The ability of VSV-G, which targets HIV-1
infection to an endocytic route, to alleviate the requirement for Nef
in HIV-1 infection, is consistent with this conclusion (1,
20). No structural or biochemical differences between wild-type
and nef-defective HIV-1 particles have been reported other
than the presence of Nef itself. However, a functional role of
virion-associated Nef in HIV-1 infection remains elusive. Our
observation that Nef enhances infection resulting from virion transcomplementation indicates that the virion modification induced by
Nef can be transferred from donor to target virions during intervirion
fusion. The modification could be the presence of Nef itself or a
Nef-associated molecule. Alternatively, Nef may modify another virion
component during assembly and/or maturation.
A surprising outcome of this study is that expression of Nef during
target virus production had no effect on infection resulting from
virion transcomplementation. This result suggests that Nef does not act
by modifying the viral core but may alter the function of the viral Env
protein complex. Schaeffer et al. have recently reported that Nef
promotes the cytoplasmic delivery of HIV-1 cores into target cells,
suggesting that Nef enhances virus-cell fusion (31).
Although Nef may act at multiple stages in HIV-1 infection, our results
are more consistent with a mechanism involving the enhancement of
postentry events. Using donor virus particles containing both HIV-1 Env
and VSV-G, we observed a minimal effect of Nef on infection of
CD4-negative target cells. However, infection required both CD4 and an
appropriate coreceptor on target virions, demonstrating that
intervirion fusion was not significantly enhanced by VSV-G. We conclude
that Nef does not enhance the fusion of donor and target virions.
Infectivity enhancement by Nef is not unique to the HIV-1 Env
glycoproteins, as the infectivity of HIV-1(A-MLV) pseudotyped particles
is also strongly stimulated by Nef. We have recently observed that Nef
does not enhance the infectivity of A-MLV-based retroviral vector
particles, indicating that the viral Env protein complex is not
sufficient for Nef-mediated infectivity enhancement (J. Zhou and C. Aiken, unpublished observations).
How could Nef modify the function of the viral envelope without
affecting fusion? HIV-1 budding occurs from glycolipid-enriched microdomains of the plasma membrane (26). Nef may alter
the lipid composition and structure of the envelope so as to enhance release of the core into the cytoplasm following fusion. Additional studies will be needed to define precisely the mechanism by which Nef
stimulates HIV-1 infection.
 |
ACKNOWLEDGMENTS |
We thank Lorraine Albritton, Uta von Schwedler, Wes Sundquist,
Hans-Georg Krausslich, and Dana Gabuzda for plasmids and Dean Ballard,
Terry Dermody, Sebastian Joyce, Paul Spearman, and members of the Aiken
laboratory for constructive suggestions. The following reagents were
obtained through the NIH AIDS Research and Reference Reagent Program:
pSV-E-MLV-env, pSV
MLV-env
and
pBABE.CCR5 from Ned Landau; recombinant soluble CD4 from Ray Sweet,
SmithKline Beecham; and HIV-1 gp120 monoclonal antibody 2G12 from
Hermann Katinger.
This work was supported by grants AI40364 and AI47056 from the National
Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Vanderbilt University School of Medicine, A-5301 Medical Center North, Nashville, TN 37232-2363. Phone: (615)
343-7037. Fax: (615) 343-7392. E-mail:
chris.aiken{at}mcmail.vanderbilt.edu.
 |
REFERENCES |
| 1.
|
Aiken, C.
1997.
Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.
J. Virol.
71:5871-5877[Abstract].
|
| 2.
|
Aiken, C., and D. Trono.
1995.
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
J. Virol.
69:5048-5056[Abstract].
|
| 3.
|
Balliet, J. W., and P. Bates.
1998.
Efficient infection mediated by viral receptors incorporated into retroviral particles.
J. Virol.
72:671-676[Abstract/Free Full Text].
|
| 4.
|
Bukovsky, A.,
T. Dorfman,
A. Weimann, and H. G. Gottlinger.
1997.
Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease.
J. Virol.
71:1013-1018[Abstract].
|
| 5.
|
Charneau, P.,
M. Alizon, and F. Clavel.
1992.
A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication.
J. Virol.
66:2814-2820[Abstract/Free Full Text].
|
| 6.
|
Chazal, N.,
G. Singer,
C. Aiken,
M.-L. Hammarskjold, and D. Rekosh.
2001.
Human immunodeficiency virus type 1 particles pseudotyped by envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.
J. Virol.
75:4014-4018[Abstract/Free Full Text].
|
| 7.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 8.
|
Chen, Y.-L.,
D. Trono, and D. Camaur.
1998.
The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity.
J. Virol.
72:3178-3184[Abstract/Free Full Text].
|
| 9.
|
Chowers, M. Y.,
M. W. Pandori,
C. A. Spina,
D. D. Richman, and J. C. Guatelli.
1995.
The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation.
Virology
212:451-457[CrossRef][Medline].
|
| 10.
|
Chowers, M. Y.,
C. A. Spina,
T. J. Kwoh,
N. J. S. Fitch,
D. D. Richman, and J. C. Guatelli.
1994.
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.
J. Virol.
68:2906-2914[Abstract/Free Full Text].
|
| 11.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[CrossRef][Medline].
|
| 12.
|
Emerman, M., and M. Malim.
1998.
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.
Science
280:1880-1884[Abstract/Free Full Text].
|
| 13.
|
Endres, M. J.,
S. Jaffer,
B. Haggarty,
J. D. Turner,
B. J. Doranz,
P. J. O'Brien,
D. L. Kolson, and J. A. Hoxie.
1997.
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
Science
278:1462-1464[Abstract/Free Full Text].
|
| 14.
|
Hanna, Z.,
D. G. Kay,
N. Rebai,
A. Guimond,
S. Jothy, and P. Jolicoeur.
1998.
Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.
Cell
95:163-175[CrossRef][Medline].
|
| 15.
|
He, J.,
Y. Chen,
M. Farzan,
H. Choe,
A. Ohagen,
S. Gartner,
J. Busciglio,
X. Yang,
W. Hofmann,
W. Newman,
C. R. Mackay,
J. Sodroski, and D. Gabuzda.
1997.
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
Nature
385:645-649[CrossRef][Medline].
|
| 16.
|
Kestler, H. W., III,
D. J. Ringler,
K. Mori,
D. L. Panicali,
P. K. Sehgal,
M. D. Daniel, and R. C. Desrosiers.
1991.
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651-662[CrossRef][Medline].
|
| 17.
|
Kirchhoff, F.,
T. C. Greenough,
D. B. Brettler,
J. L. Sullivan, and R. C. Desrosiers.
1995.
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
N. Engl. J. Med.
332:228-232[Free Full Text].
|
| 18.
|
Kotov, A.,
J. Zhou,
P. Flicker, and C. Aiken.
1999.
Association of Nef with the human immunodeficiency virus type 1 core.
J. Virol.
73:8824-8830[Abstract/Free Full Text].
|
| 19.
|
Landau, N. R., and D. R. Littman.
1992.
Packaging system for rapid production of murine leukemia virus vectors with variable tropism.
J. Virol.
66:5110-5113[Abstract/Free Full Text].
|
| 20.
|
Luo, T.,
J. L. Douglas,
R. L. Livingston, and J. V. Garcia.
1998.
Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems.
Virology
241:224-233[CrossRef][Medline].
|
| 21.
|
Maeda, T.,
K. Kawasaki, and S. Ohnishi.
1981.
Interaction of influenza virus hemagglutinin with target membrane lipids is a key step in virus-induced hemolysis and fusion at pH 5.2.
Proc. Natl. Acad. Sci. USA
78:4133-4137[Abstract/Free Full Text].
|
| 22.
|
Mangasarian, A.,
M. Foti,
C. Aiken,
D. Chin,
J.-L. Carpentier, and D. Trono.
1997.
The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane.
Immunity
6:67-77[CrossRef][Medline].
|
| 23.
|
Mariani, R.,
F. Kirchhoff,
T. C. Greenough,
J. L. Sullivan,
R. C. Desrosiers, and J. Skowronski.
1996.
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection.
J. Virol.
70:7752-7764[Abstract].
|
| 24.
|
Miller, M. D.,
M. T. Warmerdam,
I. Gaston,
W. C. Greene, and M. B. Feinberg.
1994.
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
J. Exp. Med.
179:101-113[Abstract/Free Full Text].
|
| 25.
|
Miller, M. D.,
M. T. Warmerdam,
K. A. Page,
M. B. Feinberg, and W. C. Greene.
1995.
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
J. Virol.
69:570-584[Abstract].
|
| 26.
|
Nguyen, D. H., and J. E. K. Hildreth.
2000.
Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.
J. Virol.
74:3264-3272[Abstract/Free Full Text].
|
| 27.
|
Pandori, M. W.,
N. J. S. Fitch,
H. M. Craig,
D. D. Richman,
C. A. Spina, and J. C. Guatelli.
1996.
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.
J. Virol.
70:4283-4290[Abstract].
|
| 28.
|
Peter, F.
1998.
HIV Nef: the mother of all evil?
Immunity
9:433-437[CrossRef][Medline].
|
| 29.
|
Premkumar, D. R.,
X. Z. Ma,
R. K. Maitra,
B. K. Chakrabarti,
J. Salkowitz,
B. Yen-Lieberman,
M. S. Hirsch, and H. W. Kestler.
1996.
The nef gene from a long-term HIV type 1 nonprogressor.
AIDS Res. Hum. Retrovir.
12:337-345[Medline].
|
| 30.
|
Salvi, R.,
A. R. Garbuglia,
A. Di Caro,
S. Pulciani,
F. Montella, and A. Benedetto.
1998.
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor.
J. Virol.
72:3646-3657[Abstract/Free Full Text].
|
| 31.
|
Schaeffer, E.,
R. Geleziunas, and W. C. Greene.
2001.
Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.
J. Virol.
75:2993-3000[Abstract/Free Full Text].
|
| 32.
|
Schwartz, O.,
V. Marechal,
O. Danos, and J.-M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 33.
|
Sparacio, S.,
U. Zeilfelder,
T. Pfeiffer,
T. Henzler, and V. Bosch.
2000.
Membrane fusion between retroviral particles: host-range extension and vaccine prospects.
Virology
271:248-252[CrossRef][Medline].
|
| 34.
|
Wehrly, K., and B. Chesebro.
1997.
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents.
Methods
12:288-293[CrossRef][Medline].
|
| 35.
|
Welker, R.,
M. Harris,
B. Cardel, and H.-G. Krausslich.
1998.
Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity.
J. Virol.
72:8833-8840[Abstract/Free Full Text].
|
| 36.
|
Welker, R.,
H. Kottler,
H. R. Kalbitzer, and H.-G. Krausslich.
1996.
Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase.
Virology
219:228-236[CrossRef][Medline].
|
| 37.
|
White, J., and A. Helenius.
1980.
pH-dependent fusion between the Semliki Forest virus membrane and liposomes.
Proc. Natl. Acad. Sci. USA
77:3273-3277[Abstract/Free Full Text].
|
| 38.
|
White, J.,
J. Kartenbeck, and A. Helenius.
1982.
Membrane fusion activity of influenza virus.
EMBO J.
1:217-222[Medline].
|
| 39.
|
Wiegers, K.,
G. Rutter,
H. Kottler,
U. Tessmer,
H. Hohenberg, and H.-G. Krausslich.
1998.
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.
J. Virol.
72:2846-2854[Abstract/Free Full Text].
|
| 40.
|
Yee, J. K.,
T. Friedmann, and J. C. Burns.
1994.
Generation of high-titer pseudotyped retroviral with very broad host range.
Methods Cell Biol.
43:99-112.
|
Journal of Virology, July 2001, p. 5851-5859, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5851-5859.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pizzato, M., Popova, E., Gottlinger, H. G.
(2008). Nef Can Enhance the Infectivity of Receptor-Pseudotyped Human Immunodeficiency Virus Type 1 Particles. J. Virol.
82: 10811-10819
[Abstract]
[Full Text]
-
Dismuke, D. J., Aiken, C.
(2006). Evidence for a Functional Link between Uncoating of the Human Immunodeficiency Virus Type 1 Core and Nuclear Import of the Viral Preintegration Complex.. J. Virol.
80: 3712-3720
[Abstract]
[Full Text]
-
Davis, M. R., Jiang, J., Zhou, J., Freed, E. O., Aiken, C.
(2006). A Mutation in the Human Immunodeficiency Virus Type 1 Gag Protein Destabilizes the Interaction of the Envelope Protein Subunits gp120 and gp41. J. Virol.
80: 2405-2417
[Abstract]
[Full Text]
-
de Parseval, A., Bobardt, M. D., Chatterji, A., Chatterji, U., Elder, J. H., David, G., Zolla-Pazner, S., Farzan, M., Lee, T.-H., Gallay, P. A.
(2005). A Highly Conserved Arginine in gp120 Governs HIV-1 Binding to Both Syndecans and CCR5 via Sulfated Motifs. J. Biol. Chem.
280: 39493-39504
[Abstract]
[Full Text]
-
Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., Bates, P.
(2005). Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA
102: 11876-11881
[Abstract]
[Full Text]
-
Cluet, D., Bertsch, C., Beyer, C., Gloeckler, L., Erhardt, M., Gut, J.-P., Galzi, J.-L., Aubertin, A.-M.
(2005). Detection of Human Immunodeficiency Virus Type 1 Nef and CD4 Physical Interaction in Living Human Cells by Using Bioluminescence Resonance Energy Transfer. J. Virol.
79: 8629-8636
[Abstract]
[Full Text]
-
Schiavoni, I., Trapp, S., Santarcangelo, A. C., Piacentini, V., Pugliese, K., Baur, A., Federico, M.
(2004). HIV-1 Nef Enhances Both Membrane Expression and Virion Incorporation of Env Products: A MODEL FOR THE NEF-DEPENDENT INCREASE OF HIV-1 INFECTIVITY. J. Biol. Chem.
279: 22996-23006
[Abstract]
[Full Text]
-
Day, J. R., Munk, C., Guatelli, J. C.
(2004). The Membrane-Proximal Tyrosine-Based Sorting Signal of Human Immunodeficiency Virus Type 1 gp41 Is Required for Optimal Viral Infectivity. J. Virol.
78: 1069-1079
[Abstract]
[Full Text]
-
Zhou, J., Yuan, X., Dismuke, D., Forshey, B. M., Lundquist, C., Lee, K.-H., Aiken, C., Chen, C. H.
(2004). Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation. J. Virol.
78: 922-929
[Abstract]
[Full Text]
-
Ding, W., Kim, S.-J., Nair, A. M., Michael, B., Boris-Lawrie, K., Tripp, A., Feuer, G., Lairmore, M. D.
(2003). Human T-Cell Lymphotropic Virus Type 1 p12I Enhances Interleukin-2 Production during T-Cell Activation. J. Virol.
77: 11027-11039
[Abstract]
[Full Text]
-
Tobiume, M., Lineberger, J. E., Lundquist, C. A., Miller, M. D., Aiken, C.
(2003). Nef Does Not Affect the Efficiency of Human Immunodeficiency Virus Type 1 Fusion with Target Cells. J. Virol.
77: 10645-10650
[Abstract]
[Full Text]
-
Papkalla, A., Munch, J., Otto, C., Kirchhoff, F.
(2002). Nef Enhances Human Immunodeficiency Virus Type 1 Infectivity and Replication Independently of Viral Coreceptor Tropism. J. Virol.
76: 8455-8459
[Abstract]
[Full Text]
-
Lundquist, C. A., Tobiume, M., Zhou, J., Unutmaz, D., Aiken, C.
(2002). Nef-Mediated Downregulation of CD4 Enhances Human Immunodeficiency Virus Type 1 Replication in Primary T Lymphocytes. J. Virol.
76: 4625-4633
[Abstract]
[Full Text]
-
Khan, M., Garcia-Barrio, M., Powell, M. D.
(2001). Restoration of Wild-Type Infectivity to Human Immunodeficiency Virus Type 1 Strains Lacking nef by Intravirion Reverse Transcription. J. Virol.
75: 12081-12087
[Abstract]
[Full Text]
-
Motsinger, A., Haas, D. W., Stanic, A. K., Van Kaer, L., Joyce, S., Unutmaz, D.
(2002). CD1d-restricted Human Natural Killer T Cells Are Highly Susceptible to Human Immunodeficiency Virus 1 Infection. JEM
195: 869-879
[Abstract]
[Full Text]